Janux will start dosing members within the Part I trial JANX011
Janux Therapeutics has dosed the primary participant in a Part I scientific trial of JANX011, a Cluster of Differentiation 19 (CD19)-targeted bispecific candidate designed utilizing its adaptive immune response modulator (ARM) platform.
The open-label, dose-escalation examine will assess the tolerability, security, pharmacodynamics and pharmacokinetics of JANX011 in wholesome adults.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra info
The examine goals to outline key immune responses akin to B cell reminiscence reset, B cell depletion, threat of cytokine launch and T cell growth.
The trial is predicted to offer early pharmacodynamic knowledge that may affect dose choice and point out which autoimmune ailments needs to be prioritized in subsequent phases of growth.
JANX011 is meant for the therapy of autoimmune ailments by focused depletion of CD19-expressing B cells in each blood and tissues to realize a deep and long-lasting immune reset.
It represents the primary scientific candidate from Janux’s ARM platform, which goals to allow sustainable B cell depletion by leveraging adaptive immune responses whereas bettering the protection profile and comfort of immune-interventional therapies.
David Campbell, president and CEO of Janux Therapeutics, stated: “Administering JANX011 to the primary participant marks a major milestone for Janux and the primary scientific analysis of our ARM platform.
“Though JANX011 is initially being developed for autoimmune ailments, the ARM platform’s differentiated immune profile might also have broader implications for CD19-expressing ailments, together with hematological malignancies.”
Janux Therapeutics Chief Scientific Officer and co-founder Tommy DiRaimondo stated: “Based mostly on compelling preclinical knowledge, we imagine JANX011 has the potential to realize pharmacodynamic results just like these seen with CAR-T therapies, together with secure adjustments within the immune cell inhabitants and discount within the variety of autoantibodies that trigger illness, whereas offering the protection, comfort and redosing flexibility wanted for autoimmune sufferers.”
In Might 2025, Janux initiated Part Ib extension research with JANX007 within the first-in-human scientific trial ENGAGER-PSMA-01, geared toward treating superior metastatic castration-resistant prostate most cancers (mCRPC).
